Page 1

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000 cyclopharm TM Technegas T ultralute HALF YEAR 2021 RESULTS - REVENUES REBOUND Cyclopharm Ltd ABN 74 116 931 250 Unit 4 , 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au Sydney , August 23 , 2021 Radiopharmaceutical company , Cyclopharm Limited ( ASX : CYC ) ( the Company ) today announced results for the six month period ending 30 June 2021. The results include total consolidated revenue of $ 8.5 million , rebounding strongly from a COVID - 19 impacted prior corresponding six - month period ( pcp ) to June 30 , 2020. The Company maintained a 0.5 cents per share dividend for the half year . Key features of the 2021 Half Year results include : Total revenue of $ 8.5 million , up 47 % on pcp Revenues from Patient Administration Sets grew 21 % vs pcp to $ 4.5 million Technegas Generator revenue rose 75 % vs pcp to $ 1.3 million Third party distribution revenue more than doubled to $ 1.6 million Gross margin was 73.5 % of sales Strong balance sheet with a net cash position of $ 31.6 million Interim dividend maintained at 0.5 cents per share Financial Results Cyclopharm generated total revenues of $ 8.5 million for the six months to June 30 , 2021 , up 47 % on pcp , driven by a strong recovery across all products and services from a Covid - 19 impacted period in 2020. Total sales for the six months also exceeded 2019 levels , marking a return to the Company's pre - Covid growth trajectory . Cyclopharm's new third - party distribution service continued to deliver compelling growth , with revenues rising 121 % on pcp to $ 1.6 million . As third - party distribution margins are lower than those for Cyclopharm's other products , overall gross margins fell slightly to 73.5 % from 76.3 % in 1H 2020. The net loss after tax for the period was $ 3.9 million , a 30 % improvement on the net loss after tax of $ 5.6 million for pcp . Costs relating to the USFDA approval process were $ 1.2 million . Page 1 of 4 TechnegasTM per - patient consumable Patient Administration Sets ( PAS ) revenue was 21 % higher at $ 4.5 million , driven by increased consumable sales in higher margin markets . TechnegasTM Generator revenues grew 75 % to $ 1.25 million , as more generator units were installed in the Nuclear Medicine departments in the Company's established markets . Technegas ™ Service revenue of $ 0.7 million in 1H2021 was 34 % higher than 1H2020 and 12 % higher than pre - COVID - 19 service revenue in 1H2019 . Income from Cyclotek NSW Pty Ltd contributed $ 0.40 million to total revenue , up from $ 0.15 million in 1H2020 .